The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCL
December 22nd 2015Adding brentuximab vedotin (Adcetris) to frontline R-CHOP produced a greater than 80% response rate—including complete remissions in three-fourths of patients—as a treatment for CD30+ diffuse large B-cell lymphoma.
Expert Calls for More Research in Checkpoint Blockade for Upper Tract Urothelial Cancers
December 21st 2015Compelling evidence has been presented about the various checkpoint inhibitors in bladder cancer, but, additionally there have been some provocative papers looking at genomic sequencing of upper tract compared with bladder that shows certain differences
Effective Management and Prevention of Neratinib-Induced Diarrhea
Safety data from clinical trials suggest that a prophylactic regimen reduces both the severity and duration of neratinib-associated diarrhea.
Obinutuzumab/Venetoclax Combo Highly Effective in CLL
December 18th 2015Treatment with the combination of the CD20 inhibitor obinutuzumab and the BCL-2 inhibitor venetoclax was tolerable and demonstrated promising signs of efficacy for elderly patients with previously untreated chronic lymphocytic leukemia and comorbidities.
ABIM Says Disputed MOC Requirements Will Stay in Deep Freeze
December 17th 2015Several elements of the Maintenance of Certification for certifying physician competency that were suspended temporarily in February will remain in cold storage until 2018, while the ABIM works to develop a plan that is more acceptable to its physician members.
Prostate Cancer Guidelines Lack Molecular Test Recommendations
December 15th 2015When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
FDA Approves Cooling Cap to Reduce Alopecia During Chemotherapy
December 14th 2015The Dignitana DigniCap Cooling System, a computer-controlled device aimed to reduce the severity and frequency of hair loss in patients who receive neoadjuvant or adjuvant chemotherapy for breast cancer, has been cleared by the FDA as the first cooling cap for use in the United States.
FDA Grants Priority Review to Palbociclib in Pretreated HR+/HER2- Breast Cancer
December 10th 2015The FDA has granted a priority review to a supplemental new drug application for palbociclib (Ibrance) for use in combination with fulvestrant in pretreated patients with HR-positive, HER2-negative metastatic breast cancer.
FDA Approves Bendamustine Hydrochloride for CLL, NHL
December 9th 2015The FDA has approved a rapid infusion formulation of bendamustine under the trade name Bendeka for the treatment of patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.